Merck, the maker of the HIV drug Isentress (raltegravir), will extend its support of state AIDS Drug Assistance Programs (ADAPs) through the end of 2014, according to a Merck statement. In an agreement with the ADAP Crisis Task Force, Merck will continue supporting programs that provide low-income people with access to HIV medicines; Merck will also allow eligible ADAPs to obtain Isentress film-coated tablets at the same price in effect since January 2012; and it will add a fixed low price to eligible ADAPs for Isentress chewable tablets for children and adolescents with HIV.

To read the statement, click here.